Sun Pharmaceutical Industries’
subsidiary has been granted a final approval from USFDA for its Abbreviated New
Drug Applications (ANDA) for generic version of Prandin, Repaglinide tablets.
Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin
with a Para IV certification, is eligible for a 180-day marketing exclusivity
in the US. Wednesday, July 24, 2013
Epic Update : Sun Pharmaceutical Industries
Sun Pharmaceutical Industries’
subsidiary has been granted a final approval from USFDA for its Abbreviated New
Drug Applications (ANDA) for generic version of Prandin, Repaglinide tablets.
Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin
with a Para IV certification, is eligible for a 180-day marketing exclusivity
in the US. 
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment